Clinical Trial Update: A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of gefitinib (IRESSA) in relapsed and refractory small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED